Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lactobacillus salivarius + lactobacillus acidophilus + bifidobacterium bifidus BGN4 + mesalazine
- Development stage
- Unknown
- Lead developer
- BIFIDO
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Small Molecules, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral, Rectal
01
Overview
This is a combination product containing three probiotic strains (Lactobacillus acidophilus, Lactobacillus salivarius, and Bifidobacterium bifidus BGN4) along with mesalazine, an anti-inflammatory medication. The probiotic components help improve digestion, restore normal gut flora, and may reduce inflammation in the gut lining. Mesalazine is an aminosalicylate anti-inflammatory drug used to treat inflammatory bowel diseases such as ulcerative colitis and Crohn's disease. This combination may be used to treat inflammatory bowel conditions while simultaneously supporting gut microbiota.
02
Targets
COXNOS2 (Nitric Oxide Synthase 2)
Beyond the preview
Go deeper on lactobacillus salivarius + lactobacillus acidophilus + bifidobacterium bifidus BGN4 + mesalazine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lactobacillus salivarius + lactobacillus acidophilus + bifidobacterium bifidus BGN4 + mesalazine.